MCID: CLC006
MIFTS: 48

Calcinosis

Categories: Metabolic diseases

Aliases & Classifications for Calcinosis

MalaCards integrated aliases for Calcinosis:

Name: Calcinosis 12 29 54 43 15 71
Pathologically Calcified Structure 12
Pathologic Calcification 12

Classifications:



External Ids:

Disease Ontology 12 DOID:182
MeSH 43 D002114
NCIt 49 C3672
SNOMED-CT 67 6595006
UMLS 71 C0006663

Summaries for Calcinosis

Disease Ontology : 12 A calcium metabolism disease that is the result of the formation of calcium deposits in any soft tissue.

MalaCards based summary : Calcinosis, also known as pathologically calcified structure, is related to tumoral calcinosis, normophosphatemic, familial and tumoral calcinosis, hyperphosphatemic, familial, 1. An important gene associated with Calcinosis is SAMD9 (Sterile Alpha Motif Domain Containing 9), and among its related pathways/superpathways are Parathyroid hormone synthesis, secretion and action and Endochondral Ossification. The drugs Atorvastatin and Sevelamer have been mentioned in the context of this disorder. Affiliated tissues include kidney, bone and skin, and related phenotypes are growth/size/body region and cardiovascular system

Wikipedia : 74 Calcinosis is the formation of calcium deposits in any soft tissue. It is a rare condition that has many... more...

Related Diseases for Calcinosis

Diseases related to Calcinosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 562)
# Related Disease Score Top Affiliating Genes
1 tumoral calcinosis, normophosphatemic, familial 34.7 SAMD9L SAMD9
2 tumoral calcinosis, hyperphosphatemic, familial, 1 34.4 SAMD9 PHEX MEPE KL GALNT3 FGF23
3 familial tumoral calcinosis 34.0 TNF SAMD9L SAMD9 PHEX KL GALNT3
4 hyperparathyroidism 31.6 PHEX KL FGF23 CALCA
5 hyperphosphatemia 31.3 SPP1 PHEX MGP KL GALNT3 FGF23
6 secondary hyperparathyroidism 31.3 PHEX KL FGF23 CALCA
7 calciphylaxis 31.2 SPP1 MGP FGF23 AHSG
8 hypervitaminosis d 30.9 KL GALNT3 FGF23 CALCA
9 kidney disease 30.9 TNF SPP1 MGP FGF23 ENPP1 AHSG
10 primary hyperparathyroidism 30.8 KL FGF23 CALCA AHSG
11 adult dermatomyositis 30.8 TNF GPT
12 arteriosclerosis 30.8 SPP1 MGP KL GPT
13 angioid streaks 30.7 MGP GALNT3 ENPP1 AHSG
14 hyperostosis 30.6 SPP1 KL GALNT3 FGF23 ANKH
15 uremia 30.5 TNF SPP1 MGP ENPP1 AHSG
16 skin atrophy 30.5 LMNA KL FGF23
17 bone resorption disease 30.5 TNF SPP1 KL FGF23 CALCA
18 dentin dysplasia 30.5 SPP1 MEPE DMP1
19 pulmonary alveolar microlithiasis 30.5 MEPE GALNT3 FGF23
20 pseudoxanthoma elasticum 30.4 SPP1 SPARC MGP ENPP1 ANKH
21 hypophosphatemic rickets, x-linked recessive 30.4 PHEX MEPE FGF23 ENPP1 DMP1
22 chronic kidney disease 30.3 TNF SPP1 MGP KL FGF23 ENPP1
23 rickets 30.3 SPP1 PHEX MEPE KL FGF23 ENPP1
24 aortic valve disease 2 30.2 SPP1 SPARC MGP
25 dental pulp calcification 30.2 SAMD9 KL GALNT3
26 enthesopathy 30.1 TNF PHEX GALNT3 FGF23 ENPP1 DMP1
27 bone disease 30.1 TNF SPP1 SPARC PHEX FGF23 CALCA
28 paget's disease of bone 30.1 TNF SPARC CALCA
29 oncogenic osteomalacia 30.1 PHEX MEPE FGF23 DMP1
30 tympanosclerosis 29.9 TNF SPP1 CALCA
31 brittle bone disorder 29.9 SPP1 SPARC MEPE CALCA
32 hypophosphatemic rickets, autosomal dominant 29.9 PHEX MEPE KL GALNT3 FGF23 ENPP1
33 hypophosphatemia 29.8 SPP1 PHEX MEPE KL FGF23 ENPP1
34 nevus, epidermal 29.8 PHEX MEPE GALNT3 FGF23 ENPP1 DMP1
35 nephrolithiasis, calcium oxalate 29.7 SPP1 PHEX MGP KL FGF23 CALCA
36 ankylosis 29.7 TNF ENPP1 ANKH
37 osteomalacia 29.7 PHEX MEPE FGF23 ENPP1 DMP1 CALCA
38 myocardial infarction 29.3 TNF SPP1 MGP GPT ENPP1 AHSG
39 osteoporosis 29.3 TNF SPP1 SPARC MGP MEPE LMNA
40 mineral metabolism disease 28.8 SPP1 PHEX MGP MEPE KL GALNT3
41 arterial calcification of infancy 28.8 SPP1 PHEX MGP KL GALNT3 FGF23
42 tumoral calcinosis, hyperphosphatemic, familial, 2 12.7
43 tumoral calcinosis, hyperphosphatemic, familial, 3 12.7
44 crest syndrome 12.2
45 basal ganglia calcification, idiopathic, childhood-onset 12.0
46 basal ganglia calcification, idiopathic, 1 12.0
47 mandibuloacral dysplasia with type a lipodystrophy 11.9
48 dermatomyositis 11.7
49 systemic scleroderma 11.7
50 scleroderma, familial progressive 11.6

Graphical network of the top 20 diseases related to Calcinosis:



Diseases related to Calcinosis

Symptoms & Phenotypes for Calcinosis

MGI Mouse Phenotypes related to Calcinosis:

45 (show all 17)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.4 AHSG ANKH CENPB DMP1 EGR1 ENPP1
2 cardiovascular system MP:0005385 10.35 ANKH DMP1 EGR1 ENPP1 FGF23 GALNT3
3 homeostasis/metabolism MP:0005376 10.35 AHSG ANKH DMP1 EGR1 ENPP1 FGF23
4 cellular MP:0005384 10.34 ANKH CENPB DMP1 EGR1 ENPP1 GALNT3
5 hematopoietic system MP:0005397 10.31 ANKH DMP1 EGR1 FGF23 GALNT3 KL
6 immune system MP:0005387 10.3 ANKH DMP1 EGR1 ENPP1 FGF23 GALNT3
7 craniofacial MP:0005382 10.25 ANKH DMP1 ENPP1 GALNT3 KL LMNA
8 endocrine/exocrine gland MP:0005379 10.19 CENPB DMP1 EGR1 FGF23 GALNT3 KL
9 limbs/digits/tail MP:0005371 10.18 AHSG ANKH DMP1 EGR1 ENPP1 FGF23
10 integument MP:0010771 10.13 EGR1 ENPP1 FGF23 GALNT3 KL LMNA
11 hearing/vestibular/ear MP:0005377 9.99 AHSG ANKH ENPP1 KL LMNA PHEX
12 muscle MP:0005369 9.97 AHSG ANKH ENPP1 GALNT3 KL LMNA
13 liver/biliary system MP:0005370 9.91 EGR1 ENPP1 KL LMNA PHEX SPP1
14 renal/urinary system MP:0005367 9.91 DMP1 ENPP1 FGF23 GALNT3 KL LMNA
15 reproductive system MP:0005389 9.85 ANKH CENPB DMP1 EGR1 FGF23 GALNT3
16 respiratory system MP:0005388 9.56 ANKH EGR1 FGF23 KL LMNA MGP
17 skeleton MP:0005390 9.53 AHSG ANKH DMP1 EGR1 ENPP1 FGF23

Drugs & Therapeutics for Calcinosis

Drugs for Calcinosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 158)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Atorvastatin Approved Phase 4 134523-00-5 60823
2
Sevelamer Approved Phase 4 52757-95-6
3
Calcium acetate Approved, Investigational Phase 4 62-54-4
4
Alendronate Approved Phase 4 121268-17-5, 66376-36-1 2088
5
Ethanol Approved Phase 4 64-17-5 702
6 fluindione Approved, Investigational Phase 4 957-56-2
7
Apixaban Approved Phase 4 503612-47-3 10182969
8
Dalteparin Approved Phase 4 9005-49-6
9
Amlodipine Approved Phase 4 88150-42-9 2162
10
Phylloquinone Approved, Investigational Phase 4 84-80-0
11
Warfarin Approved Phase 4 81-81-2 6691 54678486
12
Phenprocoumon Approved, Investigational Phase 4 435-97-2 9908 54680692
13
Rivaroxaban Approved Phase 4 366789-02-8
14
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 6221 5280795
15
Calcitriol Approved, Nutraceutical Phase 4 32222-06-3 134070 5280453
16
Melatonin Approved, Nutraceutical, Vet_approved Phase 4 73-31-4 896
17
Menadione Approved, Nutraceutical Phase 4 58-27-5 4055
18
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 68-26-8, 11103-57-4, 22737-96-8 445354 9904001
19 Menaquinone Investigational Phase 4 1182-68-9
20
Coumarin Experimental Phase 4 91-64-5 323
21 Vasodilator Agents Phase 4
22 Antihypertensive Agents Phase 4
23 Vasoconstrictor Agents Phase 4
24 Liver Extracts Phase 4
25 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
26 calcium channel blockers Phase 4
27 Butylated Hydroxytoluene Phase 4
28 Antivitamins K Phase 4
29 Heparin, Low-Molecular-Weight Phase 4
30 Pharmaceutical Solutions Phase 4
31 Central Nervous System Depressants Phase 4
32 Hemostatics Phase 4
33 Coagulants Phase 4
34 Vitamin K Phase 4
35 naphthoquinone Phase 4
36 Vitamin MK 7 Phase 4
37 Antifibrinolytic Agents Phase 4
38 Vitamin K 2 Phase 4
39 Anticoagulants Phase 4
40 HIV Protease Inhibitors Phase 4
41 Antithrombins Phase 4
42
protease inhibitors Phase 4
43 retinol Phase 4
44 Serine Proteinase Inhibitors Phase 4
45 Retinol palmitate Phase 4
46 Antithrombin III Phase 4
47 Factor Xa Inhibitors Phase 4
48
Serine Investigational, Nutraceutical Phase 4 56-45-1 5951
49
Spironolactone Approved Phase 3 1952-01-7, 52-01-7 5833
50
Magnesium hydroxide Approved, Investigational Phase 2, Phase 3 1309-42-8

Interventional clinical trials:

(show top 50) (show all 140)
# Name Status NCT ID Phase Drugs
1 Regulation of Bone Mineralization in Renal Osteodystrophy Unknown status NCT01799317 Phase 4 Vitamin D2
2 Influence of Vitamin K2 Administration on Vessel Calcification Markers in Patients With Chronic Kidney Disease Unknown status NCT01101698 Phase 4 Vitamin K2+10μg cholecalciferol;Vitamin D
3 Can Alendronate Suppress Aortic and Coronary Artery Calcification and Improve Bone Mineral Density in Chronic Peritoneal Dialysis Patients? Unknown status NCT00299572 Phase 4 alendronate (Fosamax)
4 A Randomized Study to Evaluate the Effects of Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease (CKD) Receiving Hemodialysis Completed NCT00379899 Phase 4 cinacalcet
5 CARE-2 (Calcium Acetate (PhosLo®)/Sevelamer(Renagel®) Evaluation Study 2) Completed NCT00211939 Phase 4 calcium acetate;sevelamer;atorvastatin
6 The Effect of Replacement of Vitamin K Antagonist by Rivaroxaban With or Without Vitamin K2 Supplementation on Vascular Calcifications in Chronic Hemodialysis Patients: A Randomized Controlled Trial Completed NCT02610933 Phase 4 rivaroxaban
7 A Phase IV, Randomized, Single-center Study of the Effects of Calcitriol and Paricalcitol on Vascular Calcification in Chronic Kidney Disease Stages 3 and 4 Completed NCT00752102 Phase 4 Calcitriol (Rocaltrol®);Paricalcitol
8 Randomised Controlled Trial of the Effect of Alendronate on Vascular Calcification and Arterial Stiffness in Chronic Kidney Disease: A Pilot Study Completed NCT00395382 Phase 4 Alendronate;Placebo
9 Can Alendronate Suppress Aortic and Coronary Artery Calcification and Improve Bone Mineral Density in Chronic Peritoneal Dialysis Patients? Completed NCT00261625 Phase 4 alendronate
10 Apixaban Versus Warfarin in the Evaluation of Progression of Atherosclerotic Calcification and Vulnerable Plaque Completed NCT02090075 Phase 4 apixaban;warfarin
11 The VICTORIA Study (Vascular CalcIfiCation and sTiffness Induced by ORal antIcoAgulation) Comparison Anti-vitamin K Versus Anti-Xa. Completed NCT02161965 Phase 4 Rivaroxaban;Fluindione;Warfarin
12 Risk Factors for Vascular Calcifications in Hemodialysis Patients: to What Extent is Vitamin K2 Deficiency Involved? Completed NCT02876354 Phase 4 Menaquinone
13 Influence of Amlodipine on the Mortality of Patients With End-Stage Renal Failure (ADAM [Amlodipine and Dialysis Patients, Action on Mortality]) Completed NCT00124969 Phase 4 Amlodipine;Placebo
14 A Comparative Study of the Efficacy of Intralesional Sodium Thiosulfate Versus Intralesional Normal Saline for the Treatment of Dystrophic and Idiopathic Calcinosis Cutis, A Double-Blind Randomized Placebo-Controlled Trial Recruiting NCT03639779 Phase 4 Sodium Thiosulfate
15 Effects of Melatonin on Progression of Coronary Artery Calcification Recruiting NCT03966235 Phase 4 Melatonin 3 mg;Placebo
16 The Effect of Replacement of Vitamin K Antagonist by Rivaroxaban With or Without Vitamin K2 Supplementation on Vascular Calcifications in Chronic Hemodialysis Patients: a Randomized Controlled Trial, Extension Study Active, not recruiting NCT03799822 Phase 4 Rivaroxaban 10 MG Oral Tablet;Vitamin K Antagonist - Drug
17 Influence of Rivaroxaban Compared to Vitamin K Antagonist Treatment Upon Development of Cardiovascular Calcification in Patients With Atrial Fibrillation and/ or Pulmonary Embolism (IRIVASC- Trial) Active, not recruiting NCT02066662 Phase 4 Rivaroxaban or Marcumar
18 A Prospective, Randomized, Open-Label Trial Investigating the Effect of 1 Alpha Hydroxy Vitamin D2 on the Development of Coronary Calcification in New ESRD Patients Using the 1-84/7-84 PTH Ratio to Determine Dosing Withdrawn NCT00502268 Phase 4 Doxercalciferol administration;Doxercalciferol administered by 1-84-7-84
19 Value of Oral Phytate (InsP6) in the Prevention of Progression of the Cardiovascular Calcifications Unknown status NCT01000233 Phase 2, Phase 3
20 Calcinosis Cutis: Therapeutic Effects of Extracorporeal Shock Wave Therapy (ESWT) Completed NCT01683500 Phase 3
21 Effect of Spironolactone on the Progression of Coronary Calcification in Peritoneal Dialysis Patients Completed NCT03314493 Phase 3 Spironolactone 25Mg Tablet
22 Vitamin K Containing Nutritional Supplement for Activation of Matrix-GIa-proteins (MGP) and Inhibition of Aortic Valve Calcification Process Completed NCT00785109 Phase 3
23 Food Supplementation With Vitamin K2 to Activate MGP as an Endogenous Inhibitor of Vascular Calcification in Hemodialysis Patients Completed NCT01407601 Phase 3
24 Randomized Prospective Open Interventional Multi-centre Study on Finding the Optimal Dose of Vitamin K2 Supplements for Hemodialysis Patients Completed NCT01675206 Phase 3
25 Atorvastatin Treatment to Attenuate the Progression of Cardiovascular Disease: Prospective, Randomized, Controlled Study Completed NCT00481364 Phase 3 atorvastatin;placebo
26 Effect of Vitamin K on Age-Related Bone Loss and Vascular Calcification Completed NCT00183001 Phase 3 Vitamin K
27 The Use of Bisphosphonates to Prevent or Delay the Progression of Vascular Calcification in End-Stage Renal Disease: A Randomized Controlled Trial Completed NCT00687661 Phase 3 Bisphosphonate;Placebo
28 A Phase 3, Intravenous Sodium Thiosulfate for Acute Calciphylaxis Treatment: A Multicenter, Randomized, Double-blind, Placebo-controlled, Clinical Trial Recruiting NCT03150420 Phase 3 Sodium Thiosulfate;Placebo-Normal Saline
29 The Effect of Oral Magnesium Supplementation on Vascular Calcification in Chronic Kidney Disease - A Randomized Clinical Trial Recruiting NCT02542319 Phase 2, Phase 3
30 Effect of Evolocumab on Coronary Artery Plaque Volume and Composition by Coronary CTA (CCTA) and Microcalcification by F18-NaF PET: A Phase 3 Study Recruiting NCT03689946 Phase 3 Evolocumab
31 Randomized Control Trial of Oral Alfacalcidol and Coronary Artery Calcification in Predialysis Chronic Kidney Disease Unknown status NCT01364688 Phase 2 oral alfacalcidol;no drug
32 SALTIRE II and RANKL Inhibition in Aortic Stenosis Unknown status NCT02132026 Phase 2 Denosumab;Alendronic Acid;Denosumab Placebo;Alendronic Acid Placebo
33 Phase II Study of Calcitonin for Tumoral Calcinosis Completed NCT00004358 Phase 2 calcitonin
34 Novel Drug Delivery of Sodium Thiosulfate for Calcinosis Associated With Adult and Juvenile Dermatomyositis Completed NCT01572844 Phase 2 Sodium thiosulfate
35 Phase 2 Open Label Single Arm Repeat Dose Study to Assess the Effect of SNF472 on Wound Healing in Uraemic Calciphylaxis Patients Completed NCT02790073 Phase 2 SNF472
36 The Treatment Effect of Intravenous Sodium Thiosulfate on Coronary Calcification in Patients on Hemodialysis Completed NCT00720772 Phase 2 25% intravenous (IV) sodium thiosulfate
37 A Phase II Randomized, Placebo-Controlled, Double-Blinded Study Evaluating the Effects of Ataciguat (HMR1766) on Aortic Valve Calcification in Patients With Moderate Calcific Aortic Valve Stenosis Completed NCT02481258 Phase 2 Ataciguat (HMR1766)
38 The Effect of Increasing Dialysate Magnesium on Serum Calcification Propensity in Subjects With End-Stage Renal Disease Treated With Haemodialysis - A Randomised Clinical Trial Completed NCT02977117 Phase 2
39 A Double-blind, Randomised, Placebo-controlled Study to Assess the Effect of SNF472 on Progression of Cardiovascular Calcification on Top of Standard of Care in End-stage-renal-disease (ESRD) Patients on Hemodialysis (HD) Completed NCT02966028 Phase 2 SNF472;Placebo
40 An Open-label Study of Sodium Thiosulfate for Treatment of Calcinosis Associated With Juvenile and Adult Dermatomyositis Recruiting NCT03267277 Phase 2 Sodium Thiosulfate
41 The Effect of Etelcalcetide on Bone-tissue Properties and Calcification Propensity in End Stage Kidney Disease Recruiting NCT03960437 Phase 2 Etelcalcetide
42 Surgical Implantation of TRAnscatheter vaLve in Native Mitral Annular Calcification (SITRAL) Study Recruiting NCT02830204 Phase 2
43 A Pilot Study to Evaluate the Safety and Efficacy of Oral Treprostinil in the Treatment of Calcinosis in Patients With Systemic Sclerosis Active, not recruiting NCT02663895 Phase 2 Oral treprostinil
44 A Comparative Trial of Calcitriol Versus Placebo for the Preservation of Bone Mass and Strength After Kidney Transplantation Active, not recruiting NCT02224144 Phase 2 Vitamin D3;Calcitriol;Placebo
45 Treatment to Reduce Vascular Calcification In Hemodialysis Patients Using Vitamin K Active, not recruiting NCT02870829 Phase 2 menaquinone-7
46 Inhibit Progression of Coronary Artery Calcification With Vitamin K in HemoDialysis Patients: The iPACK-HD Study Active, not recruiting NCT01528800 Phase 2 Vitamin K1;Microcrystalline Methylcellulose
47 An Open-label, Non-Randomized, Single-Arm Pilot Study to Evaluate the Effectiveness of Etidronate Treatment for Arterial Calcifications Due to Deficiency in CD73 (ACDC) Active, not recruiting NCT01585402 Phase 2 Etidronate
48 The Effect of Sodium Bicarbonate (Nephrotrans®) on Calcification Propensity of Serum in Kidney Transplant Recipients Not yet recruiting NCT03301558 Phase 2 Low dose sodium bicarbonate;High dose sodium bicarbonate
49 Subcutaneous Injection of Sodium Thiosulfate for Ectopic Calcifications or Ossifications. A Pilot Study Not yet recruiting NCT03582800 Phase 2 STS
50 A Pilot Study to Evaluate Topical Sodium Thiosulfate Therapy for Calcinosis Cutis (STS-CALC) Withdrawn NCT01918904 Phase 2 Sodium thiosulfate;Placebo

Search NIH Clinical Center for Calcinosis

Cochrane evidence based reviews: calcinosis

Genetic Tests for Calcinosis

Genetic tests related to Calcinosis:

# Genetic test Affiliating Genes
1 Calcinosis 29

Anatomical Context for Calcinosis

MalaCards organs/tissues related to Calcinosis:

40
Kidney, Bone, Skin, Heart, Lung, Liver, Breast

Publications for Calcinosis

Articles related to Calcinosis:

(show top 50) (show all 3750)
# Title Authors PMID Year
1
Age-dependent inhibition of ectopic calcification: a possible role for fetuin-A and osteopontin in patients with juvenile dermatomyositis with calcinosis. 54 61
18448482 2008
2
Expression of osteonectin and matrix Gla protein in scleroderma patients with and without calcinosis. 54 61
17050587 2006
3
Cutaneous calcification in patients with end-stage renal disease: a regulated process associated with in situ osteopontin expression. 54 61
16847207 2006
4
A homozygous mutation in the lamin A/C gene associated with a novel syndrome of arthropathy, tendinous calcinosis, and progeroid features. 54 61
16278265 2006
5
Fine specificity of anti-fibrillin-1 autoantibodies in primary pulmonary hypertension syndrome. 54 61
10849372 2000
6
Kinetics of anti-fibrillin-1 autoantibodies in MCTD and CREST syndrome. 54 61
10756089 2000
7
[Diabetic macroangiopathy in humans]. 54 61
9501570 1997
8
von Willebrand factor in juvenile dermatomyositis. 54 61
7738956 1995
9
Anticentromere autoantibodies. Evaluation of an ELISA using recombinant fusion protein CENP-B as antigen. 54 61
8129780 1994
10
Long-term outcomes in Juvenile Myositis patients. 61
31303436 2020
11
Ectopic Cushing's syndrome associated with a pheochromocytoma in a dog: a case report. 61
32014021 2020
12
Further evidence that calcinosis is associated with repetitive trauma in systemic sclerosis. 61
31353058 2020
13
Treatment of calcinosis cutis in systemic sclerosis and dermatomyositis: A review of the literature. 61
31302187 2020
14
Tolerance and effect of sodium thiosulfate in calcific tendinitis of the rotator cuff. 61
31673978 2020
15
Neutrophil Extracellular Traps in Tissue and Periphery in Juvenile Dermatomyositis. 61
31403247 2020
16
Clinical and genetic analysis of idiopathic normophosphatemic tumoral calcinosis in 19 patients. 61
31535357 2020
17
Delayed septic radiation-induced calcinosis cutis long after cured anorectal cancer. 61
31820076 2020
18
[Pseudotumoral calcinosis of the wrist compressing the radial nerve in systemic sclerosis]. 61
31952956 2020
19
Loss of the disease-associated glycosyltransferase Galnt3 alters Muc10 glycosylation and the composition of the oral microbiome. 61
31882545 2020
20
Congenital Hyperphosphatemic Conditions Caused by the Deficient Activity of FGF23. 61
31965220 2020
21
Pulmonary capillary hemangiomatosis or hepatopulmonary syndrome in a patient with calcinosis, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly and telangiectasia syndrome? 61
31868804 2020
22
Association of radiographic findings in hand X-ray with clinical features and autoantibodies in patients with systemic sclerosis. 61
31214867 2020
23
Pamidronate in Treatment of Calcinosis in Juvenile Dermatomyositis. 61
31937708 2020
24
Staining of antinuclear antibodies and antibodies against removable nuclear antigens in connective tissue diseases. 61
31623944 2020
25
Surgical repair of peripheral pulmonary artery stenosis in patients without williams or alagille syndromes. 61
31958550 2020
26
Favorable outcome of pheochromocytoma in a dog with atypical Cushing's syndrome and diabetes mellitus following medical treatment: a case report. 61
31900158 2020
27
Calcinosis Cutis as the Initial Manifestation of Limited Scleroderma. 61
31985726 2020
28
Calcinosis cutis universalis. 61
31999340 2020
29
Molecular basis for fibroblast growth factor 23 O-glycosylation by GalNAc-T3. 61
31932717 2020
30
Patient and physician discordance of global disease assessment in juvenile dermatomyositis: findings from the Childhood Arthritis & Rheumatology Research Alliance Legacy Registry. 61
31941511 2020
31
Characterizing calcinosis cutis in a pediatric population. 61
31990419 2020
32
Hyperphosphataemic familial tumoral calcinosis: case report of a rare and challenging disease. 61
31213107 2020
33
Idiopathic calcinosis cutis in a young male: A cytological diagnosis with histopathological correlation. 61
32031147 2020
34
Remodelling of calcinosis cutis in a patient with scleroderma overlap syndrome. 61
31407385 2020
35
Scrotal Tumoral Calcinosis: A Rare and Easily Misdiagnosed Situation. 61
31931638 2020
36
Milia-like idiopathic calcinosis cutis of the forehead in an adult without Down's syndrome successfully treated with a CO2 laser. 61
31782594 2020
37
Calcified or ossified benign soft tissue lesions that may simulate malignancy. 61
31297550 2019
38
Tumoral calcinosis in systemic lupus erythematosus associated with fat necrosis. 61
31867787 2019
39
Long-term outcome in children with juvenile dermatomyositis: A single-center study from north India. 61
31793219 2019
40
Use of Neem oil and Hypericum perforatum for treatment of calcinosis-related skin ulcers in systemic sclerosis. 61
31875751 2019
41
Recuperation of severe tumoral calcinosis in a dialysis patient: A case report. 61
31832402 2019
42
FGF23 and Bone and Mineral Metabolism. 61
31792685 2019
43
Dermoscopic features of milia-like calcinosis cutis. 61
29512978 2019
44
Recurrence of tumoral calcinosis: a case report. 61
31910191 2019
45
Association of Short-Term Ultraviolet Radiation Exposure and Disease Severity in Juvenile Dermatomyositis: Results From the Childhood Arthritis and Rheumatology Research Alliance Legacy Registry. 61
30714338 2019
46
A Curious Case of Crystal Deposit Disease in the Petrous Bone. 61
31886097 2019
47
Subcutaneous fat necrosis of the newborn. 61
31843770 2019
48
An unusual case of idiopathic calcinosis of the eyelid. 61
30644795 2019
49
Calcinosis in scleroderma made crystal clear. 61
31449135 2019
50
Novel associations between cytokines and pulmonary involvement in juvenile dermatomyositis - a cross-sectional study of long-term disease. 61
31740970 2019

Variations for Calcinosis

Expression for Calcinosis

Search GEO for disease gene expression data for Calcinosis.

Pathways for Calcinosis

Pathways related to Calcinosis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.46 KL FGF23 EGR1
2 11.14 SPP1 MGP ENPP1
3 10.93 TNF SPP1 CALCA
4 10.45 TNF SPP1 CALCA

GO Terms for Calcinosis

Cellular components related to Calcinosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.81 TNF SPP1 SPARC KL GPT FGF23
2 extracellular matrix GO:0031012 9.56 SPARC MGP MEPE DMP1
3 extracellular region GO:0005576 9.36 TNF SPP1 SPARC MGP MEPE KL
4 endoplasmic reticulum lumen GO:0005788 9.35 SPP1 MEPE FGF23 DMP1 AHSG

Biological processes related to Calcinosis according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 post-translational protein modification GO:0043687 9.88 SPP1 MEPE FGF23 DMP1 AHSG
2 extracellular matrix organization GO:0030198 9.84 TNF SPP1 SPARC DMP1
3 skeletal system development GO:0001501 9.76 PHEX MEPE ANKH AHSG
4 fibroblast growth factor receptor signaling pathway GO:0008543 9.72 KL GALNT3 FGF23
5 cellular protein metabolic process GO:0044267 9.63 SPP1 MEPE FGF23 DMP1 CALCA AHSG
6 ossification GO:0001503 9.62 SPARC MGP DMP1 AHSG
7 response to vitamin D GO:0033280 9.58 SPP1 PHEX
8 negative regulation of glucose import GO:0046325 9.58 TNF ENPP1
9 cellular response to vitamin D GO:0071305 9.57 PHEX FGF23
10 positive regulation of chemokine biosynthetic process GO:0045080 9.56 TNF EGR1
11 cellular response to parathyroid hormone stimulus GO:0071374 9.52 PHEX FGF23
12 cellular phosphate ion homeostasis GO:0030643 9.51 FGF23 ENPP1
13 positive regulation of MAPKKK cascade by fibroblast growth factor receptor signaling pathway GO:0090080 9.49 KL FGF23
14 sequestering of triglyceride GO:0030730 9.43 TNF ENPP1
15 negative regulation of bone mineralization GO:0030502 9.43 FGF23 ENPP1 AHSG
16 response to sodium phosphate GO:1904383 9.4 PHEX FGF23
17 inorganic diphosphate transport GO:0030505 9.37 ENPP1 ANKH
18 biomineral tissue development GO:0031214 9.35 SPP1 PHEX MEPE ENPP1 DMP1
19 regulation of bone mineralization GO:0030500 9.02 MGP FGF23 ENPP1 ANKH AHSG

Molecular functions related to Calcinosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular matrix binding GO:0050840 8.8 SPP1 SPARC DMP1

Sources for Calcinosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....